Your choice after metformin: SGLT2 inhibitors or GLP-1 receptor agonists?


  • Merlin Thomas (AUS)
  • Silvio Inzucchi (USA)
  • Francesco Giorgino (ITA)


The content for empagliflozin contained in this virtual session is intended for delegates from countries regulated by the European Medicines Agency (EMA), and does not include healthcare professionals in the UK or Ireland. Prescribing information may vary depending on local approval in each country inside and outside of Europe. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.